MedAware provides patented, algorithm-rich software that performs real-time evaluation of prescribed drugs against up-to-date patient profiles, using advanced machine-learning algorithms that mine data from millions of EMRs to detect outliers in prescription behavior. The system immediately flags potentially life-threatening prescribing errors. The company has opened a North American headquarters in Stamford, Connecticut and earned validation from a Harvard Medical School study, with positive live-implementation results at Sheba Medical Center. MedAware plans to use new capital to develop additional ML-enabled decision-support solutions, broaden product coverage to more catastrophic error types, further establish its North American presence, and expand EMR integrations in the U.S. Financially, the Series A adds $8m in new financing and—together with prior grants and public-support awards—brings total funding to date to $12m. Led by CEO Gidi Stein, the company has multiple EMR integrations already underway. MedAware develops patent-pending big-data analytics and machine-learning technology for the medical prescription market. Its system analyzes large-scale Electronic Medical Record (EMR) data to automatically learn how physicians treat patients in real-life scenarios. The company is led by an experienced team with clinical, business and technical backgrounds. Founded in 2012 by CEO Gidi Stein, MedAware is based in Ra’anana, Israel. It plans to use the recent funding to drive initial sales to healthcare providers, insurance companies and large pharmacy chains. The raise positions the company for an early commercial push into provider and payer markets.

Total raised

$9M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2017